619 related articles for article (PubMed ID: 29082652)
21. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF
J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load.
Yan LB; Chen EQ; Bai L; Du LY; Chen LL; Liao J; He M; Tang H
Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):366-72. PubMed ID: 25468548
[TBL] [Abstract][Full Text] [Related]
23. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
25. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
26. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
27. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
[TBL] [Abstract][Full Text] [Related]
28. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
[TBL] [Abstract][Full Text] [Related]
29. [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
Liu Y; Liu L; Peng D; Li W; Du Y; Jia T; Chang L; Li H
Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):181-4. PubMed ID: 24824118
[TBL] [Abstract][Full Text] [Related]
30. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
[TBL] [Abstract][Full Text] [Related]
31. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
32. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
35. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
36. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
[TBL] [Abstract][Full Text] [Related]
38. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
[TBL] [Abstract][Full Text] [Related]
39. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Chang TT; Lai CL; Kew Yoon S; Lee SS; Coelho HS; Carrilho FJ; Poordad F; Halota W; Horsmans Y; Tsai N; Zhang H; Tenney DJ; Tamez R; Iloeje U
Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
